SCHEMBL1038541

SCHEMBL1038541

Cc1cccc(OCCOc2cccc(/C=C3\CCN(C(=O)Nc4ccc(C)nc4)CC3C)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.51
CYP2D6 P10635 4/20 0.51
ALDH1A1 P00352 5/20 0.41
GAA P10253 2/20 0.41
MAPK1 P28482 2/20 0.41
GFER P55789 1/20 0.41
MAPT P10636 7/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
CYP2C19 P33261 1/20 0.40
TSHR P16473 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
FAAH O00519 2/20 0.38
LMNA P02545 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GSK3B P49841 1/20 0.38
THRB P10828 1/20 0.37
RECQL P46063 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1038543 1.00 CYP3A4 (0.51) CYP3A4CYP2D6ALDH1A1GAAMAPK1
SCHEMBL1961916 0.92 CYP3A4 (0.51) CYP3A4CYP2D6ALDH1A1MAPK1MAPT
SCHEMBL1961917 0.92 CYP3A4 (0.51) CYP3A4CYP2D6ALDH1A1MAPK1MAPT
SCHEMBL1038743 0.91 CYP3A4 (0.47) CYP3A4CYP2D6ALDH1A1GAAMAPK1
SCHEMBL1038742 0.91 CYP3A4 (0.47) CYP3A4CYP2D6ALDH1A1GAAMAPK1
SCHEMBL1960687 0.91 CYP3A4 (0.49) CYP3A4CYP2D6ALDH1A1GAAMAPK1
SCHEMBL1960684 0.91 CYP3A4 (0.49) CYP3A4CYP2D6ALDH1A1GAAMAPK1
SCHEMBL1076089 0.91 CYP3A4 (0.50) CYP3A4CYP2D6ALDH1A1GAAMAPK1
SCHEMBL1076091 0.91 CYP3A4 (0.50) CYP3A4CYP2D6ALDH1A1GAAMAPK1
SCHEMBL1035939 0.91 CYP3A4 (0.49) CYP3A4CYP2D6ALDH1A1GAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144159-A1 ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS PFIZER INC 2011-06-16 US disclosed
EP-2276735-A1 ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS Pfizer Inc. (US) 2011-01-26 EP disclosed
WO-2009127944-A1 ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS PFIZER INC. (US) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144159-A1 ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS FAAH, FAAH2, PAH CYP3A4 329/4885CYP2D6 382/4885ALDH1A1 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.